Abstract：【Objective】To investigate the expression level and clinical significance of human vascular endothelial growth factor receptor-1 (FLT-1) and human chitinase protein 40 (YKL-40) in the serum of children with respiratory syncytial virus (RSV) positive.【Methods】From March 2019 to April 2021, 82 children with RSV positive were treated in Baoji Hospital affiliated to Xi'an Medical College. All children were given recombinant human interferon α-2b For injection therapy, RSV positive children were divided into effective group and ineffective group according to the clinical efficacy. The general data of the two groups of children were collected, and the factors influencing the clinical efficacy of RSV positive children were analyzed by Logistic multivariate regression, and the predictive value of serum FLT-1 and YKL-40 levels on the clinical efficacy of RSV positive children was analyzed by using the subject working characteristic (ROC) curve.【Results】 Among 82 cases of RSV positive children in this study, 59 cases (71.95%) in the effective group and 23 cases (28.05%) in the ineffective group; The children in the effective group were older than those in the ineffective group, and the levels of FLT-1 and YKL-40 were lower than those in the ineffective group, the difference was statistically significant (P<0.05); Multivariate regression analysis showed that young children and high serum levels of FLT-1 and YKL-40 were risk factors for ineffective treatment in RSV positive children (P<0.05); The ROC curve analysis results showed that the area under the ROC curve (AUC) of serum FLT-1 and YKL-40 levels predicting the clinical efficacy of RSV positive children were 0.803(95%CI:0.710-0.895) and 0.778 (95%CI:0.669-0.888), respectively. 【Conclusion】The young RSV positive children with high serum FLT-1 and YKL-40 levels are more likely to have poor clinical efficacy, and both have certain predictive value for the clinical efficacy of RSV positive children.
叶文娟, 王玉. FLT-1、YKL-40在呼吸道合胞病毒阳性患儿血清中的表达水平及其临床意义[J]. 医学临床研究, 2023, 40(12): 1909-1911.
YE Wen-juan,WANG Yu. The Expression Level and Clinical Significance of FLT-1 and YKL-40 in Serum of Children with Respiratory Syncytial Virus Positive. JOURNAL OF CLINICAL RESEARCH, 2023, 40(12): 1909-1911.
[1] GRIFFITHS C D, BILAWCHUK L M, MCDONOUGH J E, et al. IGF1R is an entry receptor for respiratory syncytial virus[J].Nature,2020,583(17):615-619.
[2] MARCANDALLI J, FIALA B, OLS S, et al. Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus[J].Cell,2019,176(6):1420-1431.
[3] THORNHILL E M, VERHOEVEN D. Respiratory syncytial virus's non-structural proteins: masters of interference[J].Front Cell Infect Microbiol,2020,10(1):225.
[4] SHIBATA T, MAKINO A, OGATA R, et al. Respiratory syncytial virus infection exacerbates pneumococcal pneumonia via Gas6/Axl-mediated macrophage polarization[J].J Clin Invest,2020,130(6):3021-3037.
[5] 冯素枝,苗莉. FLT-1、YKL-40水平变化与重症肺炎患者APACHEⅡ评分的相关性[J].中国卫生工程学,2020,19(3):424-425.
[6] 任彦红,陈丹,张广超,等. 血清25羟维生素D、YKL-40检测在诊治儿童难治性支原体肺炎中的临床意义[J].医学研究杂志,2019,48(2):121-126.
[7] 中华医学会. 临床诊疗指南:小儿内科分册[M].1版.北京:人民卫生出版社,2005:823-826.
[8] HAYDEN F G, WHITLEY R J. Respiratory Syncytial Virus Antivirals: Problems and Progress[J].J Infect Dis,2020,222(9):1417-1421.
[9] EFSTATHIOU C, ABIDI S H, HARKER J, et al. Revisiting respiratory syncytial virus's interaction with host immunity, towards novel therapeutics[J].Cell Mol Life Sci,2020,77(24):5045-5058.
[10] BALAJI R V, ANWAR M, AKHTER M Z, et al. Sphingosine-1-phosphate receptor 1 activity promotes tumor growth by amplifying VEGF-VEGFR2 angiogenic signaling[J].Cell Rep,2019,29(11):3472-3487.
[11] 孙慧,李君娥,郭艳梅,等. 儿童难治性支原体肺炎血清载脂蛋白C1和YKL-40水平变化及临床意义[J].中华实用诊断与治疗杂志,2020,34(6):592-595.
[12] 应晶. 支气管炎患儿伴发呼吸道合胞病毒感染的高危因素和预后特点[J].中国妇幼保健,2021,36(4):823-826.
2023, Vol. 40 
